CorMedix Inc at JMP Securities Life Sciences Conference Transcript
Good afternoon, everybody. I am Joe Todisco; I'm the newly appointed CEO of CorMedix. I'm excited to be wrapping up my first month in seat.
I do believe that CorMedix is an attractive investment opportunity and that DefenCath, our lead product, will address a critical unmet medical need.
DefenCath is a catheter lock solution comprising heparin and taurolidine that we are developing for the reduction of catheter-related bloodstream infections. Our initial indication will focus on catheterized hemodialysis patients. But we do believe there will be broad applications across multiple therapeutic areas where catheters are utilized in patients.
Catheter-related bloodstream infections are a substantial burden in the US healthcare system, particularly in catheterized hemodialysis patients where the annual cost to the system in additional medical expenses is over $2.3 billion per year.
Between a quarter and a third of hemodialysis patients will have a CRBSI within the first 12 months of receiving hemodialysis via a catheter. The cost to treat
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
